- Conditions
- Prostate Cancer Metastatic, Castration-resistant Prostate Cancer
- Interventions
- HC-1119, Enzalutamide
- Drug
- Lead sponsor
- Hinova Pharmaceuticals USA, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 8
- States / cities
- Denver, Colorado • Washington D.C., District of Columbia • Jeffersonville, Indiana + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- AB-3028
- Biological
- Lead sponsor
- Arsenal Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 190 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 9
- States / cities
- Duarte, California • Los Angeles, California • San Francisco, California + 6 more
- Conditions
- Cervical Cancer, Breast Cancer, Colon Cancer, NSCLC, mCRPC (Metastatic Castration-resistant Prostate Cancer), Glioblastoma, Nonsmall Cell Lung Cancer
- Interventions
- ²¹²Pb-DOTAM-GRPR1
- Drug
- Lead sponsor
- Orano Med Theranostics, SAS
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Iowa City, Iowa • Lexington, Kentucky + 3 more
- Conditions
- Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
- Interventions
- Biospecimen Collection, Bone Scan, Cabazitaxel, Carboplatin, Chest Radiography, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Prednisone
- Procedure · Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 528 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 174
- States / cities
- Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 129 more
- Conditions
- Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC, B7H3
- Interventions
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Drug
- Lead sponsor
- Aktis Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 2
- States / cities
- Miami, Florida • Grand Rapids, Michigan
- Conditions
- Prostate Cancer
- Interventions
- REGN5678, Cemiplimab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- AZD4635, Oleclumab, Durvalumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 9
- States / cities
- Denver, Colorado • Fort Myers, Florida • St. Petersburg, Florida + 6 more
- Conditions
- Castration-Resistant Prostatic Cancer, Metastasis
- Interventions
- Docetaxel, Ifinatamab Deruxtecan, MK-5684, Abiraterone, Enzalutamide, Rescue Medication
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Orange, California • San Francisco, California + 5 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- ZEN003694, Enzalutamide
- Drug
- Lead sponsor
- Zenith Epigenetics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Whittier, California + 13 more
- Conditions
- Metastatic Prostate Cancer
- Interventions
- AZD0516, AZD9574
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years · Male only
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 11
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Towson, Maryland + 8 more
- Conditions
- Prostate Cancer
- Interventions
- Satraplatin
- Drug
- Lead sponsor
- William K. Oh
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- 131I-MIP-1095
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Atezolizumab, Enzalutamide
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 39
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 33 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- FT-7051
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more
- Conditions
- Castrate Resistent Prostate Cancer
- Interventions
- BPX-201 vaccine plus AP1903
- Biological
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Dallas, Texas
- Conditions
- Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, PSA
- Interventions
- OGX-427, Abiraterone Acetate, Prednisone
- Drug
- Lead sponsor
- Costantine Albany
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 10
- States / cities
- Marina del Rey, California • Bloomington, Indiana • Goshen, Indiana + 6 more
- Conditions
- Prostatic Cancer, Castration-Resistant
- Interventions
- JSB462, AAA617
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 11
- States / cities
- Duarte, California • Santa Monica, California • Denver, Colorado + 8 more
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Enzalutamide, Abiraterone acetate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,731 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Higher-Risk Myelodysplastic Syndrome (HR-MDS), Acute Myeloid Leukemia (AML), Newly Diagnosed Intermediate/High-Risk MDS
- Interventions
- KPT-8602, ASTX727, Dexamethasone
- Drug
- Lead sponsor
- Karyopharm Therapeutics Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 277 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Pasadena, California • Aurora, Colorado + 23 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Whippany, New Jersey
- Conditions
- Advanced Prostate Cancer
- Interventions
- BKM 120, Cabazitaxel
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 3
- States / cities
- Fort Myers, Florida • Omaha, Nebraska • Nashville, Tennessee
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- BNT324, Docetaxel, Prednisone/prednisolone
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 5
- States / cities
- Rockville, Maryland • Nashville, Tennessee • Austin, Texas + 2 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC), Small Cell Lung Cancer (SCLC), Follicular Lymphoma (FL)
- Interventions
- Mervometostat (PF-06821497), Enzalutamide, Itraconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 46
- States / cities
- Tucson, Arizona • Anaheim, California • Duarte, California + 22 more
- Conditions
- Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more